Skip to main content

Table 2 Number of patients with NAFLD and cholangiocarcinoma in the included case-control studies

From: Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis

Author, year Number of CCA cases (n) Number of controls (n)
iCCA eCCA All
Total With NAFLD Total With NAFLD Total With NAFLD Total With NAFLD
Welzel et al. 2007 [10] 535 5 (0.9%) 549 4 (7.3%) 1084 9 (0.8%) 102,782 353 (0.34%)
Zhou et al. 2009 [20] 317 6 (1.9%) 317 6 (1.9%) 634 8 (1.2%)
Chang et al. 2013 [17] 2978 156 (5.2%) 2179 89 (4.1%) 5157 245 (4.8%) 20628a 410 (2.0%)
Lee et al. 2015 [18] 81 17 (21.0%) 81 17 (21.0%) 162 28 (17.3%)
Kinoshita et al. 2016 [9] 34 15 (44.1%) 34 15 (44.1%) 69 13 (18.8%)
Choi et al. 2016 [16] 1169 61 (5.2%) 1226b 52 (4.2%) 2395 113 (4.7%) 4769 181 (3.8%)
Stepien et al. 2016 [19] 34 21 (61.8%) 34 21 (61.8%) 67 25 (37.3%)
  1. eCCA Extrahepatic cholangiocarcinoma, iCCA Intrahepatic cholangiocarcinoma, NAFLD Non-alcoholic fatty liver disease
  2. aComprised 11,912 controls for iCCA cases, of whom 236 had NAFLD; and 8716 controls for eCCA cases, of whom 174 had NAFLD
  3. bIncluded 231 patients with distal CCA, of whom 15 had NAFLD; and 995 patients with perihilar CCA, of whom 37 had NAFLD